• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»seronegative myasthenia gravis

Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis

By Pallavi Madhiraju on May 9, 2026   Pharma & Biotech  

Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis

Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.

Recent Posts

  • Lumenis strengthens FoLix, ULTRApulse Alpha and Stellar M22 case with ASLMS data
  • How Zifo’s AI authoring platform could reshape clinical and CMC documentation
  • INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy
  • Pharma has a Hispanic engagement problem. Relevant+ thinks Healthy Vibras can fix it
  • What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial
  • ACROBiosystems makes HEK293 functional cell lines easier to use in global R&D workflows
  • Why PureHealth Research’s berberine GLP-1 supplement push enters a crowded evidence debate
  • Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures
  • Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market
  • Can KUBTEC Scientific lower the barrier to image-guided radiotherapy in cancer research?
  • Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis
  • Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes